2,503,109 Shares in Avalyn Pharma Inc. $AVLN Bought by Montanova Capital LLC

Montanova Capital LLC purchased a new position in Avalyn Pharma Inc. (NASDAQ:AVLN) in the 2nd quarter, Holdings Channel.com reports. The fund purchased 2,503,109 shares of the company’s stock, valued at approximately $82,402,000. Avalyn Pharma accounts for about 1.4% of Montanova Capital LLC’s investment portfolio, making the stock its 22nd largest holding. Montanova Capital LLC owned about 0.06% of Avalyn Pharma at the end of the most recent quarter.

Separately, Bank of New York Mellon Corp bought a new position in shares of Avalyn Pharma during the second quarter valued at about $1,321,000.

Avalyn Pharma Trading Up 0.1%

AVLN stock opened at $34.73 on Tuesday. The stock has a market capitalization of $1.54 billion and a PE ratio of -1.52. The company has a 50-day moving average price of $31.85. The company has a debt-to-equity ratio of 0.04, a current ratio of 33.12 and a quick ratio of 33.12. Avalyn Pharma Inc. has a 12-month low of $24.15 and a 12-month high of $40.17.

Avalyn Pharma (NASDAQ:AVLN) last posted its earnings results on Wednesday, August 12th. The company reported ($0.98) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.05. Equities analysts predict that Avalyn Pharma Inc. will post -3.81 EPS for the current year.

Analyst Upgrades and Downgrades

AVLN has been the subject of a number of recent research reports. Guggenheim assumed coverage on Avalyn Pharma in a research note on Monday, May 25th. They issued a “buy” rating and a $80.00 target price for the company. Jefferies Financial Group initiated coverage on Avalyn Pharma in a research report on Monday, May 25th. They set a “buy” rating and a $52.00 price target on the stock. Wall Street Zen cut Avalyn Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Morgan Stanley boosted their price objective on Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Thursday, August 13th. Finally, Weiss Ratings started coverage on Avalyn Pharma in a research note on Thursday, August 13th. They set a “sell (d+)” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $60.00.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.